Supriya Lifescience

Supriya Lifescience OCF/Debt

The Operating Cash Flow to Debt Ratio of Supriya Lifescience (SUPRIYA.NS) as of Oct 29, 2026 is 3,591.96 %. In the previous year, Operating Cash Flow to Debt Ratio was 3,207.53 % — a change of 11.99% (higher).

OCF/Debt

3,591.96 %

YoY

11.99%

Last updated:

Operating Cash Flow to Debt Ratio of Supriya Lifescience is 2026 3,591.96 % . Operating Cash Flow to Debt Ratio of Supriya Lifescience was 2025 3,207.53 % . It decreases by 11.99% higher compared to the previous year.

The Supriya Lifescience OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2019
52.69 INR
Jan 1, 2020
137.32 INR
Jan 1, 2021
110.72 INR
Jan 1, 2022
178.01 INR
Jan 1, 2023
294.58 INR
Jan 1, 2024
2,064.63 INR
Jan 1, 2025
3,207.53 INR
Jan 1, 2026
3,591.96 INR
The Supriya Lifescience OCF/Debt history
YEAROCF/DebtYoY
3,591.96 %+11.99%
3,207.53 %+55.36%
2,064.63 %+600.86%
294.58 %+65.49%
178.01 %+60.78%
110.72 %-19.37%
137.32 %+160.60%
52.69 %+293.64%
13.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Supriya Lifescience Stock analysis

What does Supriya Lifescience do? Supriya Lifescience Ltd. generates revenue through the manufacturing and export of active pharmaceutical ingredients (APIs) focused on niche therapeutic segments. The company produces approximately 38 API products, including Chlorphenamine Maleate, Pheniramine Maleate, and Cetirizine DiHCL, which address antihistamine, analgesic, vitamin, anesthetics, and anti-asthma therapies. These products are exported to around 86 countries, targeting pharmaceutical manufacturers and healthcare providers seeking specialized chemical compounds for drug formulations. The firm's manufacturing facilities in Maharashtra support the production of bulk drugs and pharmaceutical chemicals, with a strong emphasis on research and development to maintain its niche market position. The company's product portfolio includes specialized compounds such as Bisoprolol Fumarate, Nicorandil, and Mecobalamin, which cater to specific medical needs in cardiovascular and neurological treatments. By concentrating on high-demand therapeutic areas like antihistamines and anti-asthma solutions, Supriya Lifescience Ltd. serves pharmaceutical companies globally that require reliable sources of API raw materials. Its export-driven model ensures steady demand from international clients across diverse healthcare markets. Supriya Lifescience Ltd. leverages its research and development capabilities to develop and refine its API offerings, ensuring compliance with global pharmaceutical standards. The firm's focus on niche products allows it to differentiate itself in a competitive market, attracting buyers who prioritize specialized chemical solutions over generic alternatives. With a manufacturing base in Maharashtra, the company efficiently scales production to meet the growing global demand for its targeted therapeutic APIs. Supriya Lifescience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Supriya Lifescience stock

Operating Cash Flow to Debt Ratio of Supriya Lifescience is 3,591.96 % in 2026.

Operating Cash Flow to Debt Ratio of Supriya Lifescience changed from 3,207.53 % to 3,591.96 %, representing a 11.99% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Supriya Lifescience since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Supriya Lifescience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Supriya Lifescience

All Key Metrics — Supriya Lifescience